Keypoints:
- US health funding ended September 30
- Zimbabwe rejected a proposed $367m deal
- HIV financing now faces greater pressure
ZIMBABWE faces a major health financing test after US funding for its health programmes ended on September 30, following Harare’s rejection of a proposed $367m bilateral agreement that would have supported HIV treatment, tuberculosis, malaria and other public health services.
The argument over the failed deal is now giving way to a more immediate question: whether Zimbabwe can find enough domestic money to protect years of progress against HIV and keep essential services running as one of its biggest health donors pulls back.
Zimbabwe’s National AIDS Council warned Parliament days before the cutoff that the country’s AIDS Levy was no longer enough to meet the growing demands of the national HIV response.
Amon Mpofu, NAC’s monitoring and evaluation director, said the country needed to widen its domestic funding base as international support declined.
‘We therefore need an expanded base of domestic financing to sustain the gains we have made and meet emerging needs,’ Mpofu said.
HIV gains face a funding test
Zimbabwe has an estimated 1.3 million people living with HIV, according to NAC. About 97 percent know their status, 98 percent of those diagnosed are on treatment and 96 percent of those receiving treatment have achieved viral suppression.
Those figures reflect years of investment by Zimbabwe and international partners.
The United States has been central to that effort. US programmes have supported HIV testing and treatment, tuberculosis services, laboratory systems, health workers and disease surveillance.
The US Embassy said about 1.2 million men, women and children were receiving HIV treatment through US-supported programmes when talks over the new agreement collapsed. Washington has also said its health assistance to Zimbabwe since 2006 amounted to nearly $2bn.
That support did not disappear from clinics overnight on October 1. The State Department said implementing partners would be given a short period to wind down operations and manage the transition.
But the funding has ended, and Zimbabwe now has to absorb more of the burden.
NAC says the three percent AIDS Levy has helped shield the national response from previous funding shocks. It is no longer enough, however, to carry the growing cost of treatment, prevention and related health needs on its own.
The pressure facing Zimbabwe is part of a wider shift in African health financing as international aid declines< and governments are pushed to mobilise more of their own resources.
Why Zimbabwe walked away
The dispute dates to February, when Zimbabwe walked away from negotiations over the five-year US health agreement.
The proposed deal would have provided $367m for programmes covering HIV, tuberculosis, malaria, maternal and child health and preparedness for disease outbreaks.
US Ambassador Pamela Tremont made the consequence of Zimbabwe’s decision clear before the September deadline.
‘With Zimbabwe’s decision to decline a bilateral health MOU, U.S.-supported health programs will conclude at the end of September,’ Tremont said.
Harare’s objections centred on provisions dealing with health data and biological resources.
Government spokesman Nick Mangwana described the proposed arrangement as unequal.
‘At its core, the arrangement was asymmetrical,’ he said.
Mangwana argued that Zimbabwe was being asked to share biological resources and health data over an extended period without a guarantee that it would gain access to vaccines, diagnostics or treatments that might eventually be developed from them.
Reuters reported Zimbabwe’s concerns over sensitive health data and biological resources when Harare withdrew from the negotiations in February.
That was Zimbabwe’s interpretation of the proposed terms. Washington has presented its new approach differently, saying its America First Global Health Strategy is intended to increase national responsibility, improve accountability and move countries towards greater self-reliance.
Other African states push back
The disagreement is not unique to Zimbabwe.
Ghana has also rejected a proposed US health arrangement over concerns about data access, while Zambia spent months resisting similar provisions.
In late September, Zambia’s Foreign Minister Mulambo Haimbe said Washington had agreed to remove disputed data-sharing terms from a proposed $1.5bn agreement and separate the health negotiations from a critical-minerals deal. The US State Department had not publicly confirmed those changes.
The latest development followed the earlier US-Zambia dispute over more than $1bn in proposed health support reported by Africa Briefing.
Other African governments have signed agreements under the new model. The State Department told The Washington Post that 35 governments had signed bilateral health agreements by September 30.
Washington says the shift is part of a broader move away from open-ended aid towards agreements in which partner governments put more of their own money into health systems.
The difficult part starts now
For Zimbabwe, the policy argument has now become a practical test.
Tremont has said the US wants its relationship with Harare to focus increasingly on trade and investment, including agriculture, energy, technology, infrastructure and mining.
But Zimbabwe’s health authorities must deal with the more immediate consequences of the funding exit.
The AIDS Levy gives the country a domestic financing mechanism that many African states do not have. Even so, NAC’s warning is clear: it cannot carry the response alone.
Harare’s decision to reject the agreement was framed around sovereignty and control over national health data. The question now is whether that position can be backed by enough domestic financing to prevent treatment gaps and protect the gains Zimbabwe has made against HIV.
That will determine whether the end of US health funding becomes a damaging disruption — or the point at which Zimbabwe begins financing more of its own health response.
